“The Prolyl Oligopeptidase Inhibitor KYP‑2047 Is Not Readily Bioavailable to Bloodstream Form Trypanosomes and Human Myelocytic Leukemia Cells”. 2015. Journal of Pharmaceutical Negative Results 6 (1): 7-10. https://mail.pnrjournal.com/index.php/home/article/view/84.